I think you're mistaken in one sense. Canntab are product ready for the shelf here in Canada, they've got a distributor and should be on shelves in August (assuming health canada approves the product line, but it's mostly a formality).
The issue CGB has, is that Canntab only pay CGB if they are the distributor in Australia or South East Asia. Both of which appear not to be high on the Canntab priority list. Canntab doesn't appear to have licensing to export from Canada currently (they have a processing/sales license), and their corporate presentation points to Canada being their first target and the USA being their second. The regions which CGB service may not have product revenue for 2-4 years depending on profit margins and the ability to expand manufacturing.
CGB Price at posting:
0.8¢ Sentiment: None Disclosure: Not Held